Stanford experience with chemotherapy for metastatic prostate cancer.
Torti
F M
FM
Division of Oncology, Stanford University Medical Center, Ca. 94305.
Reese
J
J
Freiha
F
F
D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D002140:California; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood; D010744:Phosphoric Monoester Hydrolases / Q000097:blood; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D004317:Doxorubicin; D010744:Phosphoric Monoester Hydrolases; D017430:Prostate-Specific Antigen; D002945:Cisplatin